|
|
 Previous Article | Table of Contents | Next Article 
Mantle cell lymphoma: a clinicopathologic study of 80 cases
LH Argatoff, JM Connors, RJ Klasa, DE Horsman and RD Gascoyne
Department of Pathology, University of British Columbia, Vancouver, Canada.
Mantle cell lymphoma (MCL) is a relatively uncommon yet distinct type of
malignant lymphoma whose clinical and pathological characterization has
been limited by the small numbers of cases published to date. We studied 80
cases of MCL seen at a single institution over 7 years to determine both
clinical and pathological prognostic factors. The patients in this study
were predominantly male (70%) and older (mean age, 63 years) and presented
with advanced-stage disease (88%). Extranodal involvement was common.
Median overall survival (OS) was 43 months. Except for performance status,
prognosis was not significantly influenced by clinical prognostic factors.
Histologically, MCL architecture was classified as diffuse (78%), nodular
(16%), or mantle zone (6%); the OS among these groups was identical.
Increased mitotic activity (>20 mitotic figures per 10 high power
fields), blastic transformation, and peripheral blood involvement at
diagnosis also predicted for a worse outcome, but bone marrow involvement
did not. The presence or absence of a translocation t(11; 14) by
cytogenetic analysis or a bcl-1 rearrangement by Southern analysis did not
significantly predict outcome. In summary, this study of 80 cases of MCL
highlights its distinctive clinicopathologic features and shows that
increased mitotic activity, blastic morphology, and peripheral blood
involvement at diagnosis are prognostically important factors.
Volume 89,
Issue 6,
pp. 2067-2078,
03/15/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Martin, A. Chadburn, P. Christos, R. Furman, J. Ruan, M. A. Joyce, E. Fusco, P. Glynn, R. Elstrom, R. Niesvizky, et al.
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
Ann. Onc.,
July 1, 2008;
19(7):
1327 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, P. Lin, Y. Shi, J. Romaguera, L. W. Kwak, et al.
A Severe Combined Immunodeficient-hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma
Clin. Cancer Res.,
April 1, 2008;
14(7):
2154 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bottcher, M. Ritgen, S. Buske, S. Gesk, W. Klapper, E. Hoster, W. Hiddemann, M. Unterhalt, M. Dreyling, R. Siebert, et al.
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
Haematologica,
April 1, 2008;
93(4):
551 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hoster, M. Dreyling, W. Klapper, C. Gisselbrecht, A. van Hoof, H. C. Kluin-Nelemans, M. Pfreundschuh, M. Reiser, B. Metzner, H. Einsele, et al.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Blood,
January 15, 2008;
111(2):
558 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ferrer, F. Bosch, N. Villamor, M. Rozman, F. Graus, G. Gutierrez, S. Mercadal, E. Campo, C. Rozman, A. Lopez-Guillermo, et al.
Central nervous system involvement in mantle cell lymphoma
Ann. Onc.,
January 1, 2008;
19(1):
135 - 141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Straus
How I Treat Mantle Cell Lymphoma
J. Oncol. Pract,
September 1, 2007;
3(5):
281 - 282.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al.
Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors
J. Clin. Oncol.,
July 1, 2007;
25(19):
2770 - 2777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi
Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways
Blood,
June 15, 2007;
109(12):
5455 - 5462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Salaverria, A. Zettl, S. Bea, V. Moreno, J. Valls, E. Hartmann, G. Ott, G. Wright, A. Lopez-Guillermo, W. C. Chan, et al.
Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature
J. Clin. Oncol.,
April 1, 2007;
25(10):
1216 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Lepelletier, V. Camara-Clayette, H. Jin, A. Hermant, S. Coulon, M. Dussiot, M. Arcos-Fajardo, C. Baude, D. Canionni, R. Delarue, et al.
Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments
Cancer Res.,
February 1, 2007;
67(3):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Belch, C. Kouroukis, M Crump, L Sehn, R. Gascoyne, R Klasa, J Powers, J Wright, and E. Eisenhauer
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
Ann. Onc.,
January 1, 2007;
18(1):
116 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
October 20, 2006;
24(30):
4867 - 4874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Richard, J Vassallo, S Valmary, R Missoury, G Delsol, and P Brousset
"In situ-like" mantle cell lymphoma: a report of two cases.
J. Clin. Pathol.,
September 1, 2006;
59(9):
995 - 996.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rudelius, S. Pittaluga, S. Nishizuka, T. H.-T. Pham, F. Fend, E. S. Jaffe, L. Quintanilla-Martinez, and M. Raffeld
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Blood,
September 1, 2006;
108(5):
1668 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Katzenberger, C. Petzoldt, S. Holler, U. Mader, J. Kalla, P. Adam, M. M. Ott, H. K. Muller-Hermelink, A. Rosenwald, and G. Ott
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
Blood,
April 15, 2006;
107(8):
3407 - 3407.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pott, C. Schrader, S. Gesk, L. Harder, M. Tiemann, T. Raff, M. Bruggemann, M. Ritgen, B. Gahn, M. Unterhalt, et al.
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
Blood,
March 15, 2006;
107(6):
2271 - 2278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Perez-Galan, G. Roue, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
Blood,
January 1, 2006;
107(1):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Romaguera, L. Fayad, M. A. Rodriguez, K. R. Broglio, F. B. Hagemeister, B. Pro, P. McLaughlin, A. Younes, F. Samaniego, A. Goy, et al.
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
J. Clin. Oncol.,
October 1, 2005;
23(28):
7013 - 7023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fernandez, E. Hartmann, G. Ott, E. Campo, and A. Rosenwald
Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways
J. Clin. Oncol.,
September 10, 2005;
23(26):
6364 - 6369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Ghobrial, D. J. McCormick, S. H. Kaufmann, A. A. Leontovich, D. A. Loegering, N. T. Dai, K. L. Krajnik, M. J. Stenson, M. F. Melhem, A. J. Novak, et al.
Proteomic analysis of mantle-cell lymphoma by protein microarray
Blood,
May 1, 2005;
105(9):
3722 - 3730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. O'Connor, J. Wright, C. Moskowitz, J. Muzzy, B. MacGregor-Cortelli, M. Stubblefield, D. Straus, C. Portlock, P. Hamlin, E. Choi, et al.
Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
J. Clin. Oncol.,
February 1, 2005;
23(4):
676 - 684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. de Leeuw, J. J. Davies, A. Rosenwald, G. Bebb, R. D. Gascoyne, M. J.S. Dyer, L. M. Staudt, J. A. Martinez-Climent, and W. L. Lam
Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes
Hum. Mol. Genet.,
September 1, 2004;
13(17):
1827 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kohlhammer, C. Schwaenen, S. Wessendorf, K. Holzmann, H. A. Kestler, D. Kienle, T. F. E. Barth, P. Moller, G. Ott, J. Kalla, et al.
Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
Blood,
August 1, 2004;
104(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Rajendran, D. R. Fisher, A. K. Gopal, L. D. Durack, O. W. Press, and J. F. Eary
High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes
J. Nucl. Med.,
June 1, 2004;
45(6):
1059 - 1064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jones, K. H. Darnell, R. A. Warnke, and J. L. Zehnder
CyclinD1/CyclinD3 Ratio by Real-Time PCR Improves Specificity for the Diagnosis of Mantle Cell Lymphoma
J. Mol. Diagn.,
May 1, 2004;
6(2):
84 - 89.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Corcione, N. Arduino, E. Ferretti, L. Raffaghello, S. Roncella, D. Rossi, F. Fedeli, L. Ottonello, L. Trentin, F. Dallegri, et al.
CCL19 and CXCL12 Trigger in Vitro Chemotaxis of Human Mantle Cell Lymphoma B Cells
Clin. Cancer Res.,
February 1, 2004;
10(3):
964 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, A. Krober, T. Katzenberger, G. Ott, E. Leupolt, T. F. E. Barth, P. Moller, A. Benner, A. Habermann, H. K. Muller-Hermelink, et al.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome
Blood,
October 15, 2003;
102(8):
3003 - 3009.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Leitch, R. D. Gascoyne, M. Chhanabhai, N. J. Voss, R. Klasa, and J. M. Connors
Limited-stage mantle-cell lymphoma
Ann. Onc.,
October 1, 2003;
14(10):
1555 - 1561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Orchard, R. Garand, Z. Davis, G. Babbage, S. Sahota, E. Matutes, D. Catovsky, P. W. Thomas, H. Avet-Loiseau, and D. Oscier
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
Blood,
June 15, 2003;
101(12):
4975 - 4981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Walsh, M. Thorselius, A. Johnson, O. Soderberg, M. Jerkeman, E. Bjorck, I. Eriksson, U. Thunberg, O. Landgren, M. Ehinger, et al.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
Blood,
May 15, 2003;
101(10):
4047 - 4054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sucker, K.-M. Klima, G. Doelken, C.-D. Heidecke, G. Lorenz, and M. Stockschlaeder
Unusual Sites of Involvement in Non-Hodgkin's Lymphoma: Case 3. Intussusception as a Rare Complication of Mantle-Cell Lymphoma
J. Clin. Oncol.,
November 1, 2002;
20(21):
4397 - 4398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Howard, J. G. Gribben, D. S. Neuberg, M. Grossbard, C. Poor, M. J. Janicek, and M. A. Shipp
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival
J. Clin. Oncol.,
March 1, 2002;
20(5):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Martinez-Climent, E. Vizcarra, D. Sanchez, D. Blesa, I. Marugan, I. Benet, F. Sole, F. Rubio-Moscardo, M. J. Terol, J. Climent, et al.
Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma
Blood,
December 1, 2001;
98(12):
3479 - 3482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Thorner, A. C. Travis, J. L. Hecht, D. S. Conrow, and D. C. Fisher
Unusual Presentations of Malignancy: Case 3. Mantle-Cell Lymphoma of Soft Tissue
J. Clin. Oncol.,
July 1, 2001;
19(13):
3291 - 3293.
[Full Text]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yatabe, R. Suzuki, K. Tobinai, Y. Matsuno, R. Ichinohasama, M. Okamoto, M. Yamaguchi, J.-i. Tamaru, N. Uike, Y. Hashimoto, et al.
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
Blood,
April 1, 2000;
95(7):
2253 - 2261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Stilgenbauer, D. Winkler, G. Ott, C. Schaffner, E. Leupolt, M. Bentz, P. Moller, H. K. Muller-Hermelink, M. R. James, P. Lichter, et al.
Molecular Characterization of 11q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma
Blood,
November 1, 1999;
94(9):
3262 - 3264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bea, M. Ribas, J. M. Hernandez, F. Bosch, M. Pinyol, L. Hernandez, J. L. Garcia, T. Flores, M. Gonzalez, A. Lopez-Guillermo, et al.
Increased Number of Chromosomal Imbalances and High-Level DNA Amplifications in Mantle Cell Lymphoma Are Associated With Blastoid Variants
Blood,
June 15, 1999;
93(12):
4365 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cuneo, R. Bigoni, G. M. Rigolin, M. G. Roberti, A. Bardi, N. Piva, R. Milani, F. Bullrich, M. L. Veronese, C. Croce, et al.
Cytogenetic Profile of Lymphoma of Follicle Mantle Lineage: Correlation With Clinicobiologic Features
Blood,
February 15, 1999;
93(4):
1372 - 1380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Geissmann, A. Ruskone-Fourmestraux, O. Hermine, P. Bourquelot, C. Belanger, J. Audouin, A. Delmer, E. A. Macintyre, B. Varet, and N. Brousse
Homing Receptor {alpha}4ß7 Integrin Expression Predicts Digestive Tract Involvement in Mantle Cell Lymphoma
Am. J. Pathol.,
December 1, 1998;
153(6):
1701 - 1705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Ives Aguilera, K. E. Bijwaard, B. Duncan, A. E. Krafft, W.-S. Chu, S. L. Abbondanzo, J. H. Lichy, and J. K. Taubenberger
Differential Expression of Cyclin | |
